Clinical Trial: A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820749) titled 'A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases' on Feb. 06.

Brief Summary: This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases

Study Start Date: Dec. 10, 2024

Study Type: INTERVENTIONAL

Condition: Asthma Bronchiale Bronchiectasis Chronic Obstructive Pulmonary Disease (COPD)

Intervention: DRUG: HSK31858

HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmac...